Full-Time

Senior Manager

Health Systems EMR Integration

Confirmed live in the last 24 hours

Natera

Natera

1,001-5,000 employees

Genetic testing and diagnostics solutions provider

Biotechnology
Healthcare

Compensation Overview

$141.6k - $177kAnnually

Senior

Company Historically Provides H1B Sponsorship

Remote in USA

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary

You match the following Natera's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • 4+ years of project management experience, with at least 2+ years doing so for health systems
  • 4+ years of leading large projects and managing teams
  • Deep knowledge of health system interoperability techniques and methods
  • Experience with healthcare integration standards such as HL7, cCDA, FHIR, etc.
Responsibilities
  • Lead and streamline the project management of health systems EMR integration engagements with Natera
  • Regularly report status of integration projects to sales, operations, and project stakeholders, and/or executive leadership team
  • Plan, prioritize, resource, deploy complex EMR integration solutions that deliver exceptional experiences to providers and patients.
  • Collaborate to develop and implement a process for requesting objective and constructive feedback from customers 30/60/90 days post implementation on customer experience during the implementation and their use of the EMR integration
  • Recruit, coach, and manage a team responsible for implementing EMR integrations with health systems
  • Implement and support best project management practices for systems implementations and upgrades.
  • Develop and use deep understanding of Natera’s users to deliver an outstanding user experience.
  • Support sales team in their efforts to present customers the best integrated solutions for their needs
  • Solicit customer feedback and funnel new requirements and product changes back into software development.
  • Coordinate and make available the necessary resources for project managers to use in achieving positive outcomes for all health systems EMR integration projects.
Desired Qualifications
  • Vendor management experience is preferred but not required.

Natera focuses on genetic testing and diagnostics, utilizing cell-free DNA (cfDNA) testing to analyze DNA fragments in the blood for cancer detection and monitoring. Their services include the Signatera test for cancer patients, organ health assessments for transplant patients, and various tests for women's health, such as prenatal screening. Natera stands out by offering a comprehensive range of specialized testing services and genetic counseling, connecting patients with counselors for personalized support. The company's goal is to improve patient care through advanced genetic testing solutions that inform medical decisions.

Company Size

1,001-5,000

Company Stage

IPO

Total Funding

$149.9M

Headquarters

Austin, Texas

Founded

2004

Simplify Jobs

Simplify's Take

What believers are saying

  • Increased adoption of liquid biopsy techniques boosts demand for Natera's cfDNA tests.
  • AI integration enhances accuracy and speed of Natera's cfDNA analysis.
  • Growing personalized medicine trend aligns with Natera's customized genetic tests.

What critics are saying

  • Hindenburg report accuses Natera of deceptive sales practices, risking legal challenges.
  • New Prospera Heart features may face slow adoption by healthcare providers.
  • Fetal RhD NIPT demand may drop post-RhIg shortage, affecting future sales.

What makes Natera unique

  • Natera's Signatera test offers personalized ctDNA analysis for cancer patients.
  • Prospera Heart test uses unique Donor Quantity Score for transplant rejection detection.
  • Panorama NIPT test is a leader in non-invasive prenatal testing with 2 million tests.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible medical plans

Investment options

Time off

Workplace perks

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

10%
MarketBeat
Nov 24th, 2024
Alpha DNA Investment Management LLC Invests $505,000 in Natera, Inc. (NASDAQ:NTRA)

Alpha DNA Investment Management LLC invests $505,000 in Natera, Inc. (NASDAQ:NTRA).

MarketBeat
Sep 22nd, 2024
Delap Wealth Advisory LLC Makes New $454,000 Investment in Natera, Inc. (NASDAQ:NTRA)

Delap Wealth Advisory LLC makes new $454,000 Investment in Natera, Inc. (NASDAQ:NTRA).

Investing.com
Jul 2nd, 2024
Natera CFO sells over $539k in company stock

In other recent news, Natera Inc. has launched the DECIPHER trial for gastroesophageal adenocarcinoma (EGC) treatment, utilizing its molecular residual disease (MRD) test, Signatera.

Yahoo Finance
Jun 17th, 2024
Natera Launches Differentiated New Feature For Prospera(Tm) Heart Test, Enhancing Detection Of Rejection For Transplant Patients

Donor Quantity Score (DQS) technique is unique to Natera, improving detection of both acute cellular rejection and antibody-mediated rejectionAUSTIN, Texas, June 17, 2024--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced the launch of Prospera Heart™ with Donor Quantity Score (DQS), further enhancing Prospera’s ability to detect rejection in heart transplant patients.Traditionally, donor-derived cell-free DNA (dd-cfDNA) tests have reported rejection risk based only on the fraction of dd-cfDNA in the blood vs. the total cfDNA (dd-cfDNA %). This fraction can be confounded by fluctuations in the amount of background total cfDNA (the denominator), which are sometimes caused by factors unrelated to the health of the transplant, including infection, surgery, or chemotherapy.Prospera Heart now incorporates a second metric – the DQS – that normalizes for the background total cfDNA. Prospera Heart with DQS combines the traditional donor fraction and the new DQS into a two-threshold algorithm, delivering a single result with more accurate risk assessment for both antibody mediated rejection (AMR) and acute cellular rejection (ACR)."Over the last two decades, Natera has pioneered cfDNA testing across women’s health, oncology, and transplant medicine," said Michael Olymbios, M.D., Medical Director, Heart Transplant. "Our extensive experience with cfDNA and Natera’s culture of continuous innovation drove us to further refine Prospera Heart by introducing this two-threshold algorithm to better serve the transplant community."A study performed at the University of Utah and the University of California San Diego showed that incorporating DQS enhanced the performance of Prospera Heart in screening for biopsy-proven active rejection

Stock Titan
Jun 17th, 2024
Natera Launches Differentiated New Feature for Prospera(TM) Heart Test, Enhancing Detection of Rejection for Transplant Patients

Natera (NASDAQ: NTRA) has launched an enhanced version of its Prospera Heart(TM) test, integrating a Donor Quantity Score (DQS) to better detect heart transplant rejection.

ETF Daily News
May 18th, 2024
Massachusetts Financial Services Co. MA Invests $27.63 Million in Natera, Inc. (NASDAQ:NTRA)

MA invests $27.63 million in Natera, Inc. (NASDAQ:NTRA).

GlobeNewswire
May 15th, 2024
NATERA ALERT: Bragar Eagel & Squire, P.C. is Investigating Natera, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Then, on March 9, 2022, Hindenburg Research ("Hindenburg") issued an investigative report (the "Hindenburg Report") alleging, among other things, that "Natera's revenue growth has been fueled by deceptive sales and billing practices aimed at doctors, insurance companies and expectant mothers."

Business Wire
May 3rd, 2024
New Natera Publication Bolsters Evidence For Extended Surveillance With Signatera™ In Breast Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced a new publication in JCO Precision Oncology reporting on the ability of its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, to detect recurrence early in patients with early-stage breast cancer. The full study can be found here. The study evaluated a total of 1,136 prospectively collected and banked plasma samples from 156 early-stage breast cancer patients enrolled in the multi-site Exploratory Breast Lead Interval Study (EBLIS). Patients were followed for up to 12 years after surgery and adjuvant chemotherapy, with blood samples collected semi-annually and then analyzed using Signatera. Key findings include:Signatera detected relapse up to 38 months earlier than imaging (median lead time 10.5 months), with an overall sensitivity of 88.2% (30/34)Relapse-free survival (RFS) and overall survival (OS) were significantly worse in patients who were ctDNA-positive, regardless of hormone receptor and HER2 subtype (HR 52.98 and 53.69, respectively)

Business Wire
May 1st, 2024
Natera Launches Fetal Rhd Nipt Supporting Ob/Gyn Physicians And Patients During Rhig Shortage

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced the launch of a new cfDNA-based fetal RhD test. This comes at a critical time for the healthcare industry, helping physicians navigate patient care given nationwide shortages of Rho(D) immune globulin therapy (RhIg). Natera’s test can be performed as early as nine weeks gestation and determines fetal RhD status from the blood of a pregnant patient, including complex pseudogene and RhD-CE-D hybrid variants. The vast majority of other NIPT laboratories do not offer fetal RhD assessment, which makes it a key differentiator in addition to Natera’s core SNP-based technology. Up to 15 percent of pregnant patients are RhD-negative1

BioSpace
May 1st, 2024
Natera Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg Shortage

AUSTIN, Texas-(BUSINESS WIRE)- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced the launch of a new cfDNA-based fetal RhD test.